Therapeutic Glaucoma

Physician presents pearls for effective use, leading to positive outcomes for patients.

Patients show impressive proptosis and diplopia responses to teprotumumab.

Arsham Sheybani, MD, offers insight on how his glaucoma patient management protocols have altered and the shift in subconjunctival surgery in light of the pandemic.

Drops can simplify dosing, improving adherence and ocular surface health

Intraocular drainage surgery may have a future for treating issues.

Consider ideas about outflow pathways, neuroprotection.

Once-daily corticosteroid treats pain, inflammation after surgery.

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Noninvasive option reduces IOP in patients with glaucoma.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Goniotomy-viscodilation cataract surgery controls IOP without medications.

Innovation, change has dominated the glaucoma specialty over the years.

Programs use detection and treatment to ease burden of eye disease.

Sustained release helps mitigate disease progression without impacting quality of life.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

Evidence-based medicine can lead to personalized care, better results for patients

Options can reduce the treatment burden for patients, leading to improved outcomes

Investigators note the need for less medication over 12-month period

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

Besides traditional medications, here are some of the many novel approaches to treat patients with glaucoma

Research is seeking benefits, options for open-angle glaucoma patients

Treatment options may expand beyond surgery, medication, and lasers